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Coadministration of albumin and furosemide in patients with for pharmacokinetic and pharmacodynamic reasons [1–6].
the nephrotic syndrome. Increased doses of FU alone or FU in combination with
Background. In patients with nephrotic syndrome, the natri- a thiazide diuretic to block distal tubular reabsorptionuretic effect of furosemide (FU) is diminished. The effect of
are recommended to overcome the hyporesponsivenesscoadministration of FU and human albumin (HA) has re-
mained controversial. to FU [7].
Methods. In a double-blind, placebo-controlled study, nine Furosemide, like other loop diuretics, is bound to
nephrotic patients (six males, 48 6 4 years) on standardized plasma protein, mainly albumin. The albumin-boundsodium chloride intake, in random order on three separate
fraction of FU reaches the abluminal site of the proximaldays, received by intravenous administration for 60 minutes
either (a) 60 mg FU plus a sham infusion, (b) 60 mg FU plus tubular epithelial cells and interacts with the anion trans-
200 ml of a 20% solution of HA, or (c) sham infusion plus 200 porter so that FU is translocated into the tubular lumen.
ml of a 20% solution of HA. Urinary volume, sodium, albumin Hypoalbuminemia diminishes the amount of albumin-and FU excretion, renal hemodynamics, and plasma atrial na-
bound FU that can interact with the anion transportertriuretic factor concentration were assessed.
and, in consequence, diminishes the FU delivery to itsResults. Administration of FU alone significantly (P , 0.01)
increased mean cumulative urinary sodium (259 6 30 mmol) site of action, that is, the ascending limb of the loop of
and volume excretion (2684 6 167 ml) in the first eight hours Henle [1, 6]. Coadministration of FU with intravenous
as compared with the HA infusion alone (118 6 12 mmol, 1827 6
albumin could theoretically improve delivery and the141 ml). The coadministration of FU and HA caused an even
natriuretic effect of FU, that is, change the pharmacoki-more marked increase (P , 0.01 vs. HA alone) of urinary
sodium (312 6 28 mmol) and volume excretion (3230 6 201 netics of FU. This approach has been shown to restore
ml); the difference to FU administration alone was significant the natriuretic action of FU in analbuminemic nephrotic
(P , 0.05). Plasma atrial natriuretic factor, serum albumin
rats [3]. In addition, albumin infusion may increase theconcentration, and urinary albumin excretion increased sig-
natriuretic effect of FU via other mechanisms, includingnificantly on both HA infusion days, whereas urinary excretion
of FU remained unchanged with HA coadministration. Glo- reversal of absolute or relative hypovolemia, and tran-
merular filtration rate (CIn) was not significantly affected by sient reversal of sodium-conserving neural or humoral
any of the infusion protocols, but effective renal plasma flow
mechanisms. In view of the many potential mechanisms,(CPAH) increased significantly on both HA infusion days.
it is not surprising that in humans the effect of coadminis-Conclusions. Coadministration of HA potentiates the action
of FU in patients with the nephrotic syndrome, but only mod- tration is controversial [4, 8–12]. The reasons for the
estly. This effect is mediated by changes in renal hemodynamics. variability of results may include differences in volume
status, renal function, type of disease causing the ne-
phrotic syndrome, etc. [13, 14].
In patients with the nephrotic syndrome, the natriuretic This double-blind, randomized, placebo-controlled
effect of furosemide (FU) is thought to be diminished cross-over study was designed to compare the diuretic
and natriuretic effects of intravenous FU in combination
with an infusion of human albumin (HA) or a shamKey words: atrial natriuretic factor, natriuresis, distal tubular reabsorp-
tion, loop diuretic, glomerulonephritis, renal hemodynamics. infusion. Nine patients with nephrotic syndrome who
were on a controlled intake of sodium chloride were
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METHODS Langen, Germany), and (c) a sham infusion (50 ml of a
0.9% NaCl solution) plus 200 ml of a 20% solution ofPatients
HA. The patients were allocated to the different treat-All consecutive patients who agreed to participate (by
ment sequences using random numbers. The intravenouswritten informed consent) and who met the entry criteria
route of FU administration was chosen to avoid potentialwere included into the study. Entry criteria included:
interference with intestinal absorption. The dose of 40urinary protein excretion above 3.5 g/24 hr (that is, ne-
g of HA (200 ml of a 20% solution) was chosen in orderphrotic range proteinuria), primary renal disease (the
to avoid a supranormal oncotic pressure [15].absence of amyloidosis or other systemic diseases), and
Patients were examined in a quiet environment whilea defined glomerular histology to minimize the heteroge-
in a recumbent position. They fasted during the first 10neity of underlying conditions (6 patients had biopsy-
hours (from 8 a.m. to 6 p.m.); afterward, they were upproven membranous glomerulonephritis and 3 minimal
and about. The infusions mentioned earlier here werechange glomerulonephritis/focal-segmental glomerulo-
given at 10 a.m. over a period of 60 minutes. Meansclerosis). Routine blood chemistry and urine analysis
arterial pressure (MAP) was measured at regular inter-were performed at entry into the study. Nine patients
vals before drug administration and thereafter. The pa-were studied (6 males, mean age 48 6 4 years; BMI 26.6 6
tients collected urine over 24 hours, from 8 a.m. to 101.6 kg/m2). Their mean 24-hour protein excretion in the
a.m., from 10 a.m. to 12 a.m., from 12 a.m. to 2 p.m.,screening phase was 12.3 6 1.3 g/24 hr, mean serum pro-
from 2 p.m. to 4 p.m., from 4 p.m. to 6 p.m., and fromtein concentration 52 6 3 g/liter, and mean arterial blood
6 p.m. to 8 a.m. of the next day. Urinary sodium, albumin,pressure (MAP) 100 6 2 mm Hg. In all but one patient,
and FU excretions were assessed in the urine samples.the renal function was within the normal range (serum
To achieve a steady state of urine flow, patients drankcreatinine concentration below 1.3 mg/dl) and the mean
a quantity of tap water that matched the urine volumeglomerular filtration rate (GFR) was 105 6 9 ml/min/
passed in the preceding period. GFR and effective renal1.73 m2. All patients had been on diuretic medication,
plasma flow were assessed using the inulin (CIn) andand this was withdrawn for at least one week prior to the
paraaminohippurate (CPAH) clearance methods as de-start of the study. At study entry, moderate (11) to
scribed elsewhere [16]. In brief, a priming dose of 1500marked (111) edema was present in all patients. Antihy-
mg inulin/m2 (Inutestt; Laevosan Co., Linz, Austria) andpertensive drugs (if present) were not washed out, but
500 mg PAH/m2 (Nephrotestt; Biologische Arbeitsge-their dosage was kept unchanged throughout the study.
meinschaft GmbH, Lich, Germany) was given at 8 a.m.
Protocol The bolus injection was followed by continuous infusions
of inulin (10 mg/m2/min) and PAH (8 mg/m2/min) main-The protocol of this study was approved by the Ethics
tained with ultraprecise pumps (Perfusor FTt; BraunCommittee of the University of Heidelberg. A double-
Melsungen, Melsungen, Germany) from 8 a.m. to 6 p.m.blind, placebo-controlled cross-over design was used. For
Both the bolus injection and the continuous infusions of10 days, patients adhered to a diet containing a standard-
inulin and PAH were administered in 0.9% NaCl solu-ized amount of sodium chloride. The diet was prepared
tion. The amount of sodium chloride administered withas precooked, deep-frozen meals with a standardized
the infusions was identical on all study days. After a 120-sodium content of 20 mmol/day (low-salt diet). To
minute equilibration period (from 8 a.m. to 10 a.m.),achieve a final daily sodium intake of approximately 80
blood samples for measurements of GFR and effectivemmol, the diet was supplemented with six slow-release
renal plasma flow were withdrawn at regular intervalssalt tablets (Ciba-Geigy, London, UK), each containing
until 6 p.m. In addition, blood samples for the measure-10 mmol of sodium. Dietary compliance was controlled
ment of atrial natriuretic factor (ANF) and serum albu-by regular measurements of 24-hour urinary sodium ex-
min concentration were withdrawn at 10 a.m., 12 a.m.,cretion. In addition, patients were instructed to keep
and 4 p.m. Body weight was measured on all study days.their daily fluid intake constant, that is, to drink approxi-
mately 2 liters of tap water. They were also advised to
Measurements and calculationsrefrain from taking a sauna, doing any sporting activity
Plasma and urine sodium concentrations were mea-or unaccustomed physical exertion for the period of the
sured with flame photometry (Eppendorf 5051t; Ham-study. On the fifth, seventh, and ninth study days, pa-
burg, Germany), and serum and urine albumin concen-tients were given in random order the following infu-
trations with nephelometry (Array Protein Systemt;sions: (a) 60 mg of FU (Lasixt; Hoechst AG, Frankfurt,
Beckmann Instruments, Munich, Germany). PlasmaGermany) dissolved in 50 ml of a 0.9% NaCl solution,
concentration of ANF was measured with radioimmuno-plus a sham infusion (200 ml of aqua ad iniectabilia),
assay, the concentration of FU in urine with fluorometry(b) 60 mg of FU dissolved in 50 ml of a 0.9% NaCl
and high-performance liquid chromatography. Urinesolution plus 200 ml of a 20% solution of HA (Normal-
Serum-Albumin Alpha 20%t; Alpha Therapeutic GmbH, samples were collected in light-protected tubes because
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Fig. 1. Individual data on urinary volume (A) and sodium (B) excretion in nine patients with nephrotic syndrome during the first eight hours
after infusion of human albumin plus sham infusion (HA 1 sham), infusion of furosemide plus sham infusion (FU1sham), or infusion of furosemide
plus human albumin (FU 1 HA). Symbols are: (s) individual data; (d) mean value. The underlying renal disease and 24-hour urinary protein
excretion on study entry in our patients were as follows: patient 1, FSGS/5.4 g; patient 2, MGN/14.7 g; patient 3, FSGS/17.8 g; patient 4, MGN/
12.2 g; patient 5, MGN/12.8 g; patient 6, FSGS/12.0 g; patient 7, MGN/4.5 g; patient 8, MGN/11.9 g; patient 9, MGN/12.5 g. Abbreviations are:
FSGS, minimal change glomerulonephritis/focal-segmental glomerulosclerosis; MGN, membranous glomerulonephritis.
Table 1. Mean cumulative urinary volume (UV), sodium (UNa),of the known photosensitivity of FU. Inulin was deter-
chloride (UCl) and albumin (UAlb) excretion in 9 patients withmined enzymatically using inulinase [17] and paraamino- nephrotic syndrome during the first 8 hours after infusion of human
albumin plus sham administration (HA 1 sham), administration ofhippurate after the method of Braton-Marshall [18]. CIn
furosemide plus infusion (FU 1 sham) or administration ofand CPAH were calculated from the delivered dose: furosemide plus human albumin (FU 1 HA)
C 5 (Ir 3 Ic)/Sc HA 1 sham FU 1 sham FU 1 HA
UV ml/8 hr 1827 6 141a 2684 6 167d 3230 6 201bwhere C is the clearance, Ir is the infusion rate (ml/min),
UNa mmol/8 hr 118 6 12a 259 6 30c 312 6 28bIc is the concentration of the analyte in the infusion fluid
UCl mmol/8 hr 105 6 11a 231 6 31c 283 6 28b(mg/ml), and Sc is the serum concentration of the analyte UAlb mg/8 hr 2641 6 538a 1601 6 323d 2709 6 508
(mg/ml). MAP was measured oscillometrically using an a P , 0.01, HA 1 sham vs. FU 1 sham
b P , 0.01, HA 1 sham vs. FU 1 HAautomatic blood pressure-monitoring device (Dinamapt;
c P , 0.05 and d P , 0.01, FU 1 sham vs. FU 1 HACritikon Co., Tampa, FL, USA).
Statistics
The predetermined primary efficacy parameters were
multiple comparisons of related data. If this test gave athe differences of mean urinary sodium and volume ex-
significant difference between treatments, a two-sidedcretions in the first eight hours after the start of infusions
Wilcoxon test for paired data was applied to compare thebetween the following protocols: (a) administration of
respective treatments. Other parameters were comparedFU plus sham infusion, (b) administration of FU plus
using the previously mentioned tests. Differences wereinfusion of HA, and (c) sham administration plus infu-
accepted as statistically significant at a P level of 0.05.sion of HA. Data were evaluated with the SPSS program
using the Friedman test, that is, a nonparametric test for Data are shown as mean 6 sem.
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Table 2. Plasma atrial natriuretic factor and serum albuminRESULTS
concentration, blood pressure and renal hemodynamics in
Furosemide alone significantly increased cumulative 9 patients with nephrotic syndrome before (10 a.m.),
as well as two hours (12 a.m.) and 6 hours (4 p.m.)sodium, chloride, and volume excretion as compared
after administration of various infusionswith the infusion of HA alone (Table 1). Coadministra-
10 a.m. 12 a.m. 4 p.m.tion of FU and HA caused an even more marked increase
of cumulative sodium, chloride, and volume excretion. Infusion of human albumin
plus sham infusionThe difference between FU plus HA versus FU plus
ANF fmol/liter 23.4 6 3.4b 35.0 6 4.3 29.6 6 5.3sham infusion was modest but significant. Figure 1 shows Serum albumin g/liter 29.9 6 2.3b 38.0 6 1.6 37.7 6 1.5d
individual data on volume and sodium excretion in pa- MAP mm Hg 97 6 3 99 6 3 98 6 3
GFR ml/min/1.73 m2 107 6 7 108 6 8 105 6 9tients during the first eight hours after administration of
ERPF ml/min/1.73 m2 585 6 46b 712 6 61e 626 6 53crespective infusions. Coadministration of FU and HA
Infusion of furosemide
was more effective even with respect to cumulative 24- plus sham infusion
ANF fmol/liter 26.4 6 4.8 21.9 6 4.4 25.7 6 4.3hour sodium and volume excretion (374 6 34 mmol,
Serum albumin g/liter 29.8 6 2.3 30.9 6 2.4 29.8 6 2.34280 6 184 ml) as compared with FU administration
MAP mm Hg 102 6 4 105 6 2 99 6 2
alone (304 6 34 ml, 3777 6 159 mmol) and with infusion GFR ml/min/1.73 m2 105 6 7 108 6 8 108 6 9
ERPF ml/min/1.73 m2 576 6 50 545 6 35 550 6 37of HA alone (193 6 13 mmol, 2867 6 176 ml).
Infusion of human albuminAn increase of mean plasma ANF and serum albumin
plus furosemide infusionconcentration was observed on both days with HA infu- ANF fmol/liter 25.1 6 3.9a 37.0 6 4.1 32.6 6 4.7c
sion, whereas MAP did not differ significantly between Serum albumin g/liter 29.4 6 2.6b 39.3 6 2.5 37.5 6 2.5d
MAP mm Hg 100 6 3 102 6 4 100 6 3the three infusion protocols (Table 2). In parallel, GFR
GFR ml/min/1.73 m2 105 6 7 106 6 9 105 6 9was unchanged, but effective renal plasma flow increased ERPF ml/min/1.73 m2 581 6 41b 732 6 51e 592 6 46
on both HA infusion days. There was no significant dif-
Abbreviations are: ANF – atrial natriuretic factor, MAP – mean arterial blood
ference in urinary FU excretion in the first eight hours pressure, GFR – glomerular filtration rate by inulin clearance, ERPF – effective
renal plasma flow by PAH-clearance.when FU was administered alone as compared with coad-
a P , 0.05 and b P , 0.01, 10 a.m. vs. 12 a.m.ministration of FU and HA. The cumulative urinary FU c P , 0.05 and d P , 0.01, 10 a.m. vs. 4 p.m.
e P , 0.01 – 12 a.m. vs. 4 p.m.excretions with infusion of FU plus sham infusion as
compared with FU plus HA infusion were similar at two
hours (23.1 6 3.6 vs. 24.0 6 3.8 mg), four hours (32.0 6
3.9 vs. 32.3 6 4.4 mg), six hours (34.3 6 3.8 vs. 34.4 6
DISCUSSION4.2 mg) and eight hours (34.9 6 3.7 vs. 35.1 6 4.2 mg).
In contrast, mean urinary albumin excretion increased This study in patients with the nephrotic syndrome
significantly with the administration of HA (Table 1). documents a modest but significant increase in urinary
The patients lost on average a total of approximately volume and sodium chloride excretion when HA was
500 mmol sodium during the six-day study period (that coadministered with FU as compared with administra-
is, urinary sodium excretion minus dietary intake plus tion of a submaximal dose of FU alone. Furthermore,
sodium infused on the study days). Because of the ran- the study identifies some mechanisms underlying the
domization of our patients to the different treatments, stimulatory effect of albumin coadministration on natri-
the mean 24-hour sodium excretion in the days after the uresis, that is, volume expansion (as documented by an
studies was similar with all treatments (82 6 11 mmol, increase of plasma ANF concentration) with a concomi-
HA 1 sham; 83 6 12 mmol, FU 1 sham; and 80 6 14 tant increase in renal plasma flow. We admit that we
mmol, FU 1 HA). The same was true for mean 24-hour did not measure PAH extraction; we cannot definitely
urinary volume excretion (2098 6 351 ml, HA 1 sham; exclude, but consider it unlikely, that there was a change
1968 6 374 ml, FU 1 sham; and 1953 6 387 ml, FU 1 in PAH extraction with no change in renal plasma flow.
HA), the mean patient body weight (78 6 6 kg, HA 1
Our findings are compatible with the view that the effectsham; 78 6 6 kg, FU 1 sham; and 78 6 6 kg, FU 1 HA),
of albumin is mainly mediated via a change in intrarenalas well as the average MAP (at 10 a.m. of the three study
hemodynamics. A direct effect of increased ANF con-days; 100 6 2 mm Hg, FU 1 HA; 103 6 2 mm Hg,
centrations on tubular sodium reabsorption after albu-FU 1 sham; and 99 6 2 mm Hg, HA 1 sham). As a
min infusion, as suggested by some studies [19, 20], isconsequence of the modest cumulative sodium loss dur-
less plausible because most studies found resistance toing the six-day study period, the mean plasma sodium
the action of ANF in the nephrotic syndrome [13].concentration in our nine patients decreased from 141 6 1
The assumption that intrarenal mechanisms are mainlyto 135 6 1 mmol/liter, and body weight decreased from
responsible for the greater natriuretic response to albu-79 6 6 to 76 6 6 kg from study day 5 to study day 10.
min coadministration is further corroborated by the ob-Table 3 gives individual data on infusions administered,
servation that albumin coadministration did not changebody weight, blood pressure, and plasma sodium concen-
tration on study days 5, 7, and 9. the pattern of urinary FU excretion with time and the
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Table 3. Individual data on randomization, body weight, blood pressure and plasma sodium concentration on 5th, 7th and 9th study day
in 9 patients with nephrotic syndrome
Patient 5th day 7th day 9th day
1 FU 1 sham (57.8/102/142) HA 1 FU (57.2/99/140) HA 1 sham (56.1/99/136)
2 HA 1 FU (114.8/95/144) FU 1 sham (111.8/91/139) HA 1 sham (110.8/91/137)
3 HA 1 FU (80.1/99/140) HA 1 sham (77.7/101/137) FU 1 sham (77.5/106/136)
4 HA 1 sham (95.3/100/138) FU 1 sham (94.5/102/137) HA 1 FU (93.1/98/135)
5 HA 1 sham (56.1/106/141) HA 1 FU (55.9/110/140) FU 1 sham (55.0/109/136)
6 HA 1 sham (86.4/89/139) HA 1 FU (86.2/92/138) FU 1 sham (85.9/95/134)
7 FU 1 sham (79.5/107/142) HA 1 sham (78.5/99/140) HA 1 FU (78.3/100/139)
8 FU 1 sham (63.1/110/141) HA 1 sham (61.7/112/138) HA 1 FU (61.1/110/138)
9 HA 1 FU (79.5/101/143) FU 1 sham (78.4/99/138) HA 1 sham (78.1/102/136)
HA 1 sham is defined as infusion of human albumin plus sham administration; FU 1 sham, administration of furosemide plus sham infusion; and HA 1 FU is
administration of furosemide plus human albumin. In brackets in consecutive order are: body weight in kg, mean arterial blood pressure in mm Hg and plasma
sodium concentration in mmol/liter.
cumulative urinary FU excretion at eight hours in these concentrations. This is in line with previous observations,
moderately hypoproteinemic patients. Although the ex- which documented that nephrotic patients can accommo-
periments of Inoue et al suggested the possibility that date substantial volume loads without an increase in
albumin infusion might increase FU delivery into tubular blood pressure [21]. It therefore seems relatively safe to
urine [3], we conclude that in our study conditions the administer albumin even in severely nephrotic patients.
albumin infusion does not alter the pharmacokinetics How do our results compare with other controlled
but definitely affects the pharmacodynamics of FU. We studies concerning the administration of albumin plus
cannot exclude, however, that the amount of unbound FU in patients with nephrotic syndrome? Previous stud-
(pharmacologically active) FU measured in the urine ies did not provide measurements of ANF [4, 11] or
does not correspond to the active (unbound) FU at its renal clearances [11]. The patients studied were also
site of action [5]. heterogeneous with respect to the underlying renal dis-
It was our intention to assess the mechanisms underlying ease, and in addition, most of these patients had impaired
the potentially higher efficacy of combination treatment renal function. Sjo¨stro¨m et al administered 40 mg of FU
in order to provide rational guidelines for the treatment and found an increase of cumulative sodium excretion
of therapy-resistant nephrotic syndrome. This intention of approximately 15% with infusion of either albumin
precluded the investigation of severely morbid patients, or the volume expander dextran [4]; patients given albu-
who cannot be maintained in a stable condition without min or dextran excreted exactly the amount of NaCl
permanent administration of diuretics, and the diuretics that had been administered. In contrast, Akcicek et al
affect the steady state because of rebound phenomenon, administered 1 mg FU per minute, that is, a maximal
fluctuations in volume status, etc. Consequently, our dose, to severely edematous nephrotic patients [11].
findings cannot necessarily be extrapolated to patients
They failed to see a further increase of sodium excretion
with more extreme degrees of nephrotic syndrome and
with coadministration of 0.5 g albumin/kg. It is notablehypoalbuminemia. We emphasize, however, that coad-
that this FU dose had increased sodium excretion fromministration of FU and albumin caused a larger diuresis
15 to 934 mmol/min, which is a substantial proportion ofand natriuresis than FU alone, even in the patient with
the filtered load. It would have been difficult to achievethe highest urinary protein excretion (17.8 g/day) and
any further increment.the lowest serum albumin concentration (18.1 g/liter;
As to the clinical management of patients with ne-Fig. 1). Because we did not have a fourth study arm with
phrotic syndrome, it emerges from our study, as well assham infusion for FU and sham infusion for albumin,
two others [4, 11], that it is more sensible to increasethe issue of whether the effect of albumin and FU was
the dose of FU than to infuse albumin. Our findings lendadditive or even interactive cannot be addressed. A mod-
credence to numerous uncontrolled clinical observationsestly negative sodium balance was observed in our pa-
that coadministration of albumin increases the natri-tients during the six-day study period. We emphasize,
uretic potency of FU at least at submaximal doses [8–10],however, that the randomized assignment to different
but does not directly address the issue of whether thetreatment arms should have eliminated any systematic
same is still true at maximal doses of FU. A potentialchange related to differences in total sodium stores.
drawback of this approach (besides the cost) is the shortWe observed no side effects. It is of note that in our
duration of albumin’s action, as the increase in urinarypatients, blood pressure did not increase after infusion
volume and sodium excretion with the combinationof albumin despite an increase in blood volume after
infusion of albumin, as documented by increased ANF treatment compared with FU monotherapy was noted
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tance in the nephrotic syndrome. J Pharmacol Exp Ther 252:1097–in only the first eight hours after administration; this has
1101, 1990
also been noted in other studies [4]. 7. Ellison DH: The physiological basis of diuretic synergism: Its role
in treating diuretic resistance. Ann Intern Med 114:886–894, 1991In conclusion, coadministration of HA increases the
8. Davison AM, Lambie AT, Verth AH, Cash JD: Salt-poor humannatriuretic action of FU in patients with the nephrotic
albumin in management of nephrotic syndrome. BMJ 1:481–484,
syndrome. The effect appears to be mainly mediated by 1974
9. Weiss RA, Schoeneman M, Greifer I: Treatment of severe ne-changes in renal hemodynamics.
phrotic edema with albumin and furosemide. NY State J Med 384:
67, 1984
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